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Background:  Dengue is a disease of major global importance. While 
most symptomatic infections are mild, a small proportion of patients 
progress to severe disease with risk of hypovolaemic shock, organ 
dysfunction and death.  In the absence of effective antiviral or disease 
modifying drugs, clinical management is solely reliant on supportive 
measures. Obesity is a growing problem among young people in 
Vietnam and is increasingly recognised as an important risk factor for 
severe dengue, likely due to alterations in host immune and 
inflammatory pathways. Metformin, a widely used anti-
hyperglycaemic agent with excellent safety profile, has demonstrated 
potential as a dengue therapeutic in vitro and in a retrospective 
observational study of adult dengue patients with type 2 diabetes. 
 This study aims to assess the safety and tolerability of metformin 
treatment in overweight and obese dengue patients, and investigate 
its effects on several clinical, immunological and virological markers of 
disease severity. 
Methods: This open label trial of 120 obese/overweight dengue 
patients will be performed in two phases, with a metformin dose 
escalation if no safety concerns arise in phase one. The primary 
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endpoint is identification of clinical and laboratory adverse events.  
Sixty overweight and obese dengue patients aged 10-30 years will be 
enrolled at the Hospital for Tropical Diseases in Ho Chi Minh City, 
Vietnam. Participants will complete a 5-day course of metformin 
therapy and be compared to a non-treated group of 60 age-matched 
overweight and obese dengue patients. 
Discussion:  Previously observed antiviral and immunomodulatory 
effects of metformin make it a promising dengue therapeutic 
candidate in appropriately selected patients. This study will assess the 
safety and tolerability of adjunctive metformin in the management of 
overweight and obese young dengue patients, as well as its effects on 
markers of viral replication, endothelial dysfunction and host immune 
responses.  
Trial registration: ClinicalTrials.gov: NCT04377451 (May 6th 2020).
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Background
Dengue is a major threat to global public health, with an 
estimated annual incidence of 390 million infections worldwide, 
leading to approximately 96 million symptomatic cases and 
22,000 deaths in more than 120 countries1. Despite increasing 
understanding of dengue pathogenesis, effective anti-viral or 
disease modifying agents are yet to be identified, and patient 
management remains reliant on judicious fluid replacement in 
response to plasma leakage during the critical phase of illness 
(usually days 4–6)2,3.
While the vast majority of symptomatic infections give rise to 
the milder form of disease, dengue fever, those that progress to 
severe disease carry significant risk of vital organ dysfunction 
and death. Several patient groups have been identified as 
being at particular risk of severe dengue, including the elderly, 
pregnant women, those with comorbid illness, and those with 
prior exposure to alternative dengue serotypes4. An important 
and increasingly recognised severe dengue risk factor is obesity, 
a condition which has had a dramatic increase in prevalence 
among Vietnamese children and adolescents over the last 
two decades5. Several observational studies have reported an 
association between obesity and severe dengue6–9. A recent 
systematic review and meta-analysis reported the odds of 
developing severe dengue to be significantly higher in obese 
children in comparison to their non-obese counterparts 
(OR = 1.38; 95%CI 1.10 - 1.73)10.
The underlying mechanism remains unknown, but could 
possibly be explained by chronic low-grade inflammation 
that is induced by being overweight or obese11,12. Adipocytes 
are known to produce pro-inflammatory cytokines and adipok-
ines, such as adiponectin, resistin and leptin, each of which 
have a role in immunomodulation. Obesity-induced leptin 
and resistin are known to be associated with many of the physi-
ological abnormalities seen in dengue, including platelet 
dysfunction, vascular inflammation, myocardial injury, endothe-
lial dysfunction13–16, and capillary hyper-permeability17–19. Addi-
tionally, it is possible that more severe infection is permitted 
by altered CD8+ T cell immunity and impairment of natural 
killer (NK) cell activity in obese hosts20,21.
Adenosine Monophosphate (AMP)-Activated protein kinase 
(AMPK) is an enzyme involved in maintaining cellular energy 
homeostasis, in particular lipid metabolism, protein synthesis 
and glucose metabolism, and has been linked to anti-inflam-
matory processes22. Obesity has been shown to down-regulate 
AMPK, either as a result of fatty acid, amino acid and 
glucose accumulation22, or due to an increase in circulating 
pro-inflammatory cytokines22,23. One consequence of AMPK 
down-regulation is the inhibition of lipid catabolism and subse-
quent boosting of de novo lipid synthesis, creating conditions 
that favour viral replication and survival within host cells24,25.
With the majority of symptomatic dengue infections leading 
to mild, self-limiting illness, development of novel treatment 
strategies should focus on patient groups at the highest risk of 
severe disease26. This study aims to assess the effect of metformin, 
a drug known to attenuate inflammatory processes particularly in 
the context of obesity, on the disease course of dengue in 
overweight and obese children and young adults.
Metformin
Metformin (dimethybiguanide) is an oral anti-hyperglycaemic 
agent. Its mechanism of action is complex and only partially 
understood, but AMPK activation is recognised as one of a 
number of key processes in modulating glucose metabolism27. 
After sixty years of use as the first-line drug to manage type 2 
diabetes mellitus (T2DM), metformin has proven to have an 
excellent safety and tolerability profile, while also demonstrat-
ing potential to have further therapeutic applications through its 
broad range of pleiotropic effects. These include antioxidant, 
anti-inflammatory and immunomodulatory properties, as well 
as aiding endothelial vascular reactivity and preservation of the 
glycocalyx layer28–30.
Evidence regarding the effectiveness of metformin in treating 
obesity is well established. The drug has demonstrated utility 
in inducing both significant weight loss and a reduction in 
the inflammatory biomarkers interferon-γ, total plasminogen 
activator inhibitor-1 (PAI-1) and the adiponectin–leptin ratio in 
obese adults with or without T2DM31–33.
Other studies have shown improved clinical outcomes with 
metformin use in a number of infectious diseases, including 
hepatitis C (HCV), tuberculosis and dengue34–39. Notably, the 
use of metformin as an adjunct in the treatment of patients with 
HCV and insulin resistance has been shown to improve rates 
of sustained virological response in comparison to standard 
anti-viral treatment alone40. Furthermore, two prospective 
trials of metformin use in patients with HCV and T2DM 
have demonstrated significant reductions in liver-related 
complications35,36.
Metformin and dengue
Several of the aforementioned effects of metformin treatment 
have prompted consideration of its use as a potential dengue 
therapeutic. Firstly, the replication of dengue virus has been 
shown to be restricted by inhibition of lipid synthesis through 
AMPK activation24,41. Furthermore, metformin’s immunomod-
ulatory effect, which facilitates NK cell activation, reduces 
T cell exhaustion profiles and enhances CD8+ T cell memory, 
could help reduce levels of peak dengue viremia and shorten 
viral clearance times39,41,42. Metformin has been shown to 
decrease dengue viral genome copies in a dose-dependent 
manner in vitro via activation of AMPK, with 90% reduction 
in NS1 secretion in infected cells41. Prevention of progression 
to severe dengue by attenuating the inflammatory mediators 
leptin and resistin is also plausible43. Additionally, metformin 
could help reverse endothelial dysfunction, a hallmark feature 
of dengue pathogenesis, by improving endothelial-dependent 
vasodilation and reducing expression of endothelial vascular 
cell adhesion molecule (VCAM) and intercellular adhesion 
molecule 1 (ICAM1)24. Recent observational evidence sug-
gests metformin use in adult dengue patients with T2DM is 
associated with reduced risk of developing severe dengue 
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(adjusted RR = 0.60, 95%CI 0.37-0.98)37. However, the mecha-
nisms underlying this association, and any relationship they 
have to obesity, require further investigation.
Aims of the trial
We hypothesize that metformin therapy given early in the course 
of disease will attenuate obesity-induced lipid-inflammatory 
mediators and improve clinical parameters in dengue patients 
with obesity. In addition, the therapy could reduce viral 
replication through AMPK activation and immunomodulation in 
such patients.
This study aims to formally assess metformin as adjunctive 
therapy for dengue in overweight and obese patients.
Methods/design
This is protocol version 4.0, dated February 10th 2020.
Design
This is an open-label study investigating metformin therapy in 
60 overweight and obese Vietnamese adults (30 patients) and 
children (30 patients). Age range of 10 to 30 years, who are 
admitted to the Hospital for Tropical Diseases (HTD) in Ho 
Chi Minh City (HCMC), Vietnam, with positive non-structural 
protein 1 (NS1) rapid test and onset of fever <72 hours prior to 
admission.
We will investigate the effects of five days of metformin treatment 
on the grounds that the critical phase of disease usually occurs 
around the fifth day of illness.
The trial will be conducted in two phases, with a dose escala-
tion between phases (Figure 1). In the initial phase (cohort 1), 
five young adults (age ≥16) and five children (age <16) with 
body mass index (BMI) >25 kg/m2 (BMI-for-age >1 standard 
deviation – SD) will be provided with a low dose of metformin 
once daily at 850mg and 500mg, respectively. If the five-day 
safety and clinical data of cohort 1 show no safety concerns, 
the study will progress to the second phase (cohort 2). This will 
include 25 adults and 25 children, who will be given a weight- 
based dose of metformin; 1000mg (500mg twice daily) for 
participants with weight <60kg, and 1500mg (1000mg mane, 
Figure 1. Trial flow chart. 
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500mg nocte) for those ≥ 60kg. Of note, the actual number 
of patients in each cohort will depend on the results of safety 
reviews. Recruitment is expected to happen over two dengue 
seasons, and discharged patients will be asked to return for a 
single outpatient follow-up (FU) visit around day 28 of illness.
The 60 patients receiving treatment will be compared to 60 
overweight or obese patients with standard of care (without 
treatment) recruited contemporaneously from the same wards, 
with the same enrolment criteria, in an ongoing observational 
study as the control arm.
Inclusion and exclusion criteria
Patients will be eligible for study enrolment if they: (i) are 
aged between 10 and 30 years; (ii) have a clinical diagnosis of 
dengue (based on World Health Organization (WHO) – Dengue 
guidelines)2; (iii) are NS1 rapid antigen test positive; (iv) have 
BMI >25kg/m2 (or BMI-for-age >1 SD); (v) are admitted within 
72 hours of fever onset; (vi) agree to come back for FU visit 
between days 21–28 of illness; and (vii) provide written informed 
consent.
Exclusion criteria include: (i) pregnancy (confirmed by either 
clinical examination or urine dipstick for human chorionic 
gonadotrophin hormone); (ii) localising features suggestive of an 
alternative diagnosis; (iii) significant diarrhoea and/or vomiting 
(>3 episodes/24 hours); (iv) history of hypersensitivity to 
metformin; (v) current use of metformin or any other regular 
hypoglycaemic agent, including insulin; (vi) current use of any 
drug with significant metformin interaction (Extended data44); 
(vii) current treatment for heart failure or recent history of 
myocardial infarction (in the last year); (viii) presence of 
severe infection at enrolment, including severe dengue, central 
nervous system infection or septicaemia; (ix) baseline lactate 
level >2.0 mmol/L; (x) baseline blood glucose level <3.9 
mmol/l (or <70 mg/dL); (xi) baseline liver impairment (alanine 
transaminase (ALT) and/or aspartate transaminase (AST) >250 
U/L); and (xii) chronic renal impairment (glomerular filtration 
rate (GRF) <30 mL/min). Patients that are deemed unlikely to 
attend FU at 28 days from fever onset because of long travelling 
distance to the clinic will also be excluded.
Primary endpoint
The primary endpoint of this study is an evaluation of the safety 
and tolerability of metformin therapy in overweight and obese 
young adults and children with dengue. The number of clinical 
and laboratory adverse events (AEs) occurring during the five 
study days (Table 1), will be compared between the treatment 
population and the non-treated controls.
Secondary endpoints
The secondary endpoints are: fever clearance time (the time 
from enrolment to sustained body temperature <37.5°C for 
48 hours); platelet nadir and highest AST/ALT between days 3 
and 8 of illness; percentage increase in haematocrit (HCT) from 
baseline (using HCT obtained at the 28 day FU visit to reflect 
baseline); plasma viraemia (area under the log
10
-transformed 
viraemia curve from study days 3 to 6); time from enrolment to 
first undetectable viraemia and first negative NS1 measurement; 
trend over time (5 days) in VCAM1, CRP, leptin, adiponectin, 
low density lipoprotein (LDL), and AMPK phosphorylation; 
and magnitude of activated/proliferating T and NK cells as well 
Table 1. Adverse events.
1- Worsening level of consciousness (fall in GCS ≥ 2 points)
2- Change in blood pressure (PP < 20 mmHg, SBP < 90 mmHg or unmeasurable BP)
3- Vomiting (≥ 3 episodes separated by 15 minutes/ 24 hours)
4- Epigastric abdominal pain
5- Diarrhoea (≥ 5 episodes/24 hours)
6- Mucosal bleeding
7- Rash, urticaria
8- Increased lactate (≥ 3 mmol/L)
9- Episode of hypoglycaemia (glucose < 3.9 mmol/L or < 70 mg/dL)
10- Increased liver enzyme (AST or ALT > 400 U/L)
11- Acute kidney injury (eGFR reduction of >50% or < 30 ml/mn/1,73m2 or plasma 
creatinine >2 fold increase from baseline)
12- Thrombocytopenia (Platelet < 20.000/uL)
13- Other event, specify: [________________________________________]
Grade of the event 
Mild: Discomfort noticed but no disruption of normal daily activities
Moderate: Discomfort sufficient to reduce or affect daily activity
Severe: Inability to perform daily activity
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as frequency and phenotype of dengue-specific CD4+ and CD8+ 
T cells, quantified by flow cytometry at enrolment and hospital 
discharge.
Screening, enrolment and retention
Patients aged between 10 and 30 years that are admitted to one 
of the three study wards of the HTD, HCMC, Vietnam, with 
clinical suspicion of dengue and less than 72 hours of fever are 
invited to participate in the trial. After giving consent, patients 
are screened for their eligibility to commence treatment with 
the trial drug by the study physicians. Blood samples are 
collected to test for NS1, and AST, ALT and creatinine levels and 
in female patients, a urine sample is collected for a pregnancy 
test. Glucose and lactate levels are measured using point-of-care 
(POC) tests.
All patients will be asked to come back for a final FU visit at 
28 days after the onset of fever. Patients will be contacted 
3–5 days prior to the FU visit to arrange an appropriate appoint-
ment date and time. Any case who misses the FU visit will be 
contacted by phone either to reschedule the visit or to collect 
information if patients could not arrange their time to come 
back. If the patients stay in the hospital for longer than 5 days, 
due to AEs or any other reason, the treatment for these cases 
will be at discretion of the attending physicians. No further 
blood samples or study procedures will be performed from this 
point onward. However, the final outcome at discharge will 
be collected in the case report form (CRF; Extended data44).
At discharge, the participants will be offered a referral to 
nutrition specialists for a consultation of overweight/obesity 
management. Patients will also be provided with leaflets on 
healthy eating and lifestyle behaviours.
Safety reviews
The trial will be conducted in two phases, with a dose escalation 
if no safety concerns arise during the low dose stage. Metformin 
dosing will begin at 500mg (children) and 850mg (adults) once 
daily for 5 days in cohort 1. Daily patient safety reviews will 
be performed by study doctors using clinical and laboratory 
data to decide whether patients are safe to continue taking the 
study drug.
The study drug will be stopped if participants: (1) request 
withdrawal from the study; (2) develop any AEs, including 
severe renal impairment (GFR below 30mL/min/1.73m2), 
elevated lactate to ≥ 3 mmol/L, severe liver involvement 
(AST/ALT > 400U/L), severe diarrhoea (≥ 5 episodes of loose 
stool/day), persistent vomiting (≥ 3 episodes/hour or ≥ 4 / 6hours) 
and hypoglycaemia (blood glucose < 3.9 mmol/l or < 70 mg/dL); 
(3) develop severe dengue (defined as admission to intensive 
care unit); or (4) are intolerant of metformin.
All AEs occurring during the trial/or until the FU visit at around 
day 28 of illness, will be recorded in the CRF, and whether 
or not attributed to trial medication. Specific AEs are shown 
in Table 1. Laboratory events will be graded according to 
Common Terminology Criteria for Adverse Events (CTCAE) 
definitions. Clinical events will be assessed as mild, moderate, or 
severe. If the event is serious and not only related to the progres-
sion to severe dengue, or is fatal, then a serious AE form must 
be completed and the OUCRU CTU notified within 24 hours.
In cases of discontinuation due to AEs, participants will be 
followed up until the events have resolved or stabilised. A Data 
Monitoring Committee (DMC) review will take place after 
day 5 data is fully available for the first ten patients enrolled in 
cohort 1. Following satisfactory safety review of the tenth 
patient, metformin doses for all remaining patients (cohort 
2) will be weight-based; 5 days of 1000mg (500mg twice 
daily) for those weighing <60kg and 5 days of 1500mg (1000mg 
mane, 500mg nocte) for those weighing ≥60kg. All AEs and 
serious adverse events (SAEs) will be recorded and reported to 
the Ethics Committees (ECs) for review. Further DMC meetings 
will take place 6 monthly to review enrolment, AEs, treatment 
received and FU information, and any other requested data.
Treatment and drug dispensation
Metformin will be kept in a dry location below 30°C, in a 
secure area. A study pharmacist will make up and label 
individual-participant treatment packs with a trial number. Each 
pack contains sufficient study drug for 5 days of treatment and 
will be distributed to study wards as required. All medication 
storage and administration will be regulated through the central 
pharmacy to ensure good quality and control of medication 
handling.
Patients will be recruited into either cohort 1 (low dose) or 
cohort 2 (high dose). Study drugs will be administered as 
directly-observed-therapy. Patients will take the first dose of 
study drug with a light snack as soon as possible after 
enrolment. The remaining doses will be taken after meals. In 
case of vomiting within 30 minutes of taking the treatment, one 
replacement dose will be given. However, if patients continue 
vomiting after taking the replacement dose, no extra drug will be 
given thereafter.
Data collection
Clinical evaluation. Patients will be reviewed daily until 
discharge. All clinical symptoms and signs will be recorded 
in the CRF. An ultrasound scan will be performed on day 5-6 
of illness to detect evidence of fluid accumulation. General 
management decisions will be at the discretion of the attend-
ing ward doctors. Details of all AEs and SAEs will be recorded 
on specific forms, together with an assessment as to whether 
the events are likely to have been related to any treatment 
received. All SAEs will be reported promptly to the DMC 
and ECs according to policy.
Laboratory evaluation. Full blood count (FBC) and POC 
glucose and lactate tests will be undertaken daily until discharge. 
An additional POC glucose test will be performed before their 
evening meal.
In addition, levels of serum albumin, transaminases (ALT/AST), 
creatinine, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
Page 6 of 12
Wellcome Open Research 2020, 5:160 Last updated: 06 OCT 2020
triglycerides, and C-reactive protein (CRP) will be measured 
on alternate days. All tests will be done more frequently when 
clinically indicated.
Research samples collected daily until discharge will be 
used for dengue diagnostics (NS1 antigen detection and PCR 
assays). Residual blood from FBC samples will be collected 
for daily plasma viraemia levels. Serology tests (Capture 
IgM/IgG ELISAs) will be performed on enrolment (acute) and 
discharge/FU (convalescent) samples. Other laboratory inves-
tigations will include endothelial, inflammatory and lipid 
biomarkers (VCAM1, syndecan-1, leptin, adiponectin), immu-
nological tests (T cell phenotype and functional analysis), 
and immunometabolism (AMPK phosphorylation). RNA will 
be extracted from a blood sample collected on study day 2, 
and will be sequenced to investigate gene expression in the 
metformin treatment group in comparison to the non-treatment 
group.
At day 28 of illness, final routine (FBC, biochemistry) and 
research blood samples will be taken to check whether patients 
have fully recovered from the acute dengue episode.
Statistical considerations
Sample size. This is an exploratory study focusing primarily 
on safety, and there are no preliminary data regarding the 
effects of metformin in dengue on which to base a sample size 
calculation. A target sample size of 60 patients was chosen 
based on clinical judgement and feasibility considerations. 
Using the trend in VCAM over time, which is one of the 
secondary endpoints, by assuming a slope of change in 
concentration over time at 0.34 (log
2
VCAM concentration 
per day, data based on biomarkers of endothelial function in 
dengue), we conducted a power calculation using a t-test to 
compare effects on endothelial function between two groups. 
It is suggested this study will have a power of 80% to detect a 
difference of at least 0.023 (log
2
VCAM concentration per day) 
in the slope of change.
Statistical analysis. The primary analysis population will include 
all patients from cohort 1 and cohort 2, plus 60 controls as 
mentioned previously. Baseline characteristics and outcomes 
will be summarised for each treatment group. The cohort of 
patients enrolled in this study will form the active treatment 
group, while the control group will consist of overweight and 
obese dengue patients that participated in a matched cohort 
observational study, none of whom received metformin therapy. 
Continuous variables will be described using medians and 
quartiles, while categorical variables will be described in terms 
of frequencies and percentages.
The primary endpoint (number of AEs), will be compared 
between the treatment groups using negative binomial regres-
sion model. The clinical, biomarker, immunological will be 
compared between the treatment arms using linear regression 
or random effects model for continuous endpoints, and Cox 
regression for time-to-event endpoints (fever clearance time, 
time to first undetectable viremia measurement, time to first 
negative NS1 measurement). All comparisons will be adjusted for 
age, sex, and day of illness, as patients will not be randomized. 
For percentage increase in HCT and area under the curve of 
viraemia, comparisons will be also adjusted for the pre-dose value 
of the respective marker.
Ethical considerations
Ethical approval
The protocol, informed consent forms, assent forms and 
patient information sheets have been reviewed and approved by 
the ECs of the Hospital for Tropical Diseases in Ho Chi Minh 
City (CS/BND/19/34), the Vietnamese Ministry of Health 
(24/CN-HÐÐÐ) and the Oxford Tropical Research Ethics 
Committee (OxTREC reference: 36-19). The Investigator will 
submit and, where necessary, obtain approval from the above 
committees for all amendments to the originally approved 
documents.
Informed consent and information sheet
All patients entering the study must give written informed 
consent. The study physician will describe the purpose of 
the study, the study procedures, possible risks/benefits, the 
rights and responsibilities of participants, and alternatives to 
enrolment. The patient or parent/guardian will be invited to 
ask questions which will be answered by study staff, and they 
will be provided with appropriate numbers to contact if they 
have any questions subsequently. If the patient or parent/guard-
ian agrees to participate, they will be asked to sign informed 
consent/assent forms (ICFs; Extended data44). A copy of the 
form, with signature, will be given to them to keep. In addition 
to the procedures above, illiterate signatories will have the ICF 
read to them in the presence of a witness who will sign to 
confirm this.
Patients, who are between 10 and 18 years of age, will be 
asked to sign the assent form in which, the study purpose and 
procedures will be explained to them in child friendly terms. 
Their parent/guardian will be asked to sign the consent form 
as well to give permission for their child to participate in the 
study.
Confidentiality
Patients who enter the trial will be given a unique identifica-
tion number. This number will be used on both laboratory 
specimens and CRFs. The study wards and the research 
unit have the facilities to store study information securely. 
Only study staff will have access to the password-protected 
computer where entered data is stored. After conclusion of 
the study, data will be stored in a safe place. Any scientific 
publications or reports will not identify any patient by name 
or initials. When the research team reviews the clinical notes, 
they are also bound by professional confidentiality.
Data monitoring and trial steering committees
A Trial Steering Committee (TSC) will be formed to provide 
overall supervision of the conduct of the trial and provide 
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advice through its independent Chair. The ultimate decision 
for the continuation of the trial lies with the TSC. In particular, 
the TSC will concentrate on progress of the trial, adherence to 
the protocol, patient safety, and the consideration of new 
information.
An independent DMC will be set up consisting of qualified 
volunteers with the necessary knowledge of clinical trials and 
statistics. The DMC will review the protocol and agree to a 
data review schedule and reporting requirements before the 
study commences. All data reviewed by the DMC will be 
in the strictest confidence. A DMC charter will outline its 
responsibilities and operations (Extended data44).
Monitoring will then be carried out approximately annually 
by OUCRU CTU staff. The frequency, type and intensity 
of routine monitoring and the requirements for triggered 
monitoring will be detailed in the monitoring plan, which will 
also detail the procedures for review and sign-off. The monitor-
ing will adhere to the principles of ICH GCP and the monitoring 
plan.
Data collection and management
All study data will be recorded on standard CRFs and entered 
on the CliRes database. The participants will be identified by a 
unique study specific number and/or code in any database. 
The name and any other identifying detail will not be included 
in any stored electronic CRFs. Direct access will be granted 
to authorized representatives from the University of Oxford 
and any host institution for monitoring and/or audit of the 
study to ensure compliance with regulations. Original paper 
documents will be stored at the OUCRU-CTU for 15 years 
after which paper files will be scanned and archived 
electronically. Electronic data will be stored indefinitely on a 
secure OUCRU-VN server for a minimum period of 10 years 
and paper copies will be destroyed securely.
Spirit checklist
A SPIRIT checklist for this trial protocol is attached (Reporting 
guidelines44).
Data sharing and dissemination
In line with research transparency and greater access to data 
from trials, OUCRU’s clinical trials are registered at Clinical-
Trials.gov and a data sharing policy is in place. Data exchange 
complies with Information Governance and Data Security 
policies in all of the relevant countries.
Participants will not be individually informed of results. Data 
from this study will be published in peer-reviewed journals. 
Authorship and reporting of this work will follow interna-
tional guidelines and all authors will have made a noteworthy 
contribution to the work.
Trial status
We expect that this trial will start recruiting patients in June 
2020.
Discussion
Despite increasing investment in strategies to prevent infection, 
dengue remains a major global pathogen, with extremely high 
associated health, social and economic disease burden45. Severe 
dengue can be rapidly life threatening as a result of plasma 
leakage, hypovolaemic shock and subsequent end organ 
damage, and is known to disproportionately affect overweight 
and obese individuals. Although optimal supportive care is 
largely successful in permitting recovery from most dengue 
infections, effective therapeutic agents are desperately needed to 
enable treatment of patients with the greatest disease severity. 
Metformin has previously demonstrated therapeutic potential 
due to observed anti-viral and immunomodulatory effects, and 
an association with reduced risk of severe dengue in adults 
with T2DM. Additionally, its low cost and excellent safety 
profile in the treatment of T2DM make metformin a prime 
candidate for use in appropriately selected patients on a mass 
scale. This study will assess the safety and tolerability of 
metformin in the context of dengue infection, and whether 
metformin treatment early in the course of disease is clinically 
beneficial for overweight and obese children and young adults. 
It will also provide a key insight into the effects of metformin 
on markers of viral replication, endothelial dysfunction and 
the host immune response in this patient group.
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
Oxford University Research Archive: Oxford University 
Clinical Research Unit Metformin trial supporting documents, 
https://doi.org/10.5287/bodleian:5Rk2p9EVK44.
-      Consent form
-      Participant information sheet
-      DMC charter
-      Case Report Form
-      Drug interactions
Reporting guidelines
Oxford University Research Archive: SPIRIT checklist for 
‘Metformin as adjunctive therapy for dengue in overweight 
and obese patients: a protocol for an open-label clinical trial 
(MeDO)’, https://doi.org/10.5287/bodleian:5Rk2p9EVK44.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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